# France Celiac Disease Treatment Market > France Celiac Disease Treatment Market Research Report By Treatment Type (Gluten Free Diet, Vitamin and Minerals Supplements, Medical Therapies) and By End User (Hospitals and Clinics, Research Centers, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 10.78% - **2024:** $ 27.48 Million - **2025:** $ 30.44 Million - **2035:** $ 84.77 Million - **Key Players:** Gluten Free Holdings (US), General Mills (US), Kraft Heinz (US), Nestle (CH), Dr. Schar (IT), Boulder Brands (US), Canyon Bakehouse (US), Udi's Gluten Free (US) **Report ID:** MRFR/HC/49601-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/france-celiac-disease-treatment-market-51358 --- ## Market Summary ## **France Celiac Disease Treatment Market Overview** As per MRFR analysis, the France Celiac Disease Treatment Market Size was estimated at 32.96 (USD Million) in 2023. The France Celiac Disease Treatment Market Industry is expected to grow from 36.6(USD Million) in 2024 to 210 (USD Million) by 2035. The France Celiac Disease Treatment Market CAGR (growth rate) is expected to be around 17.213% during the forecast period (2025 - 2035) **Key France Celiac Disease Treatment Market Trends Highlighted** The France Celiac Disease Treatment Market is witnessing several notable trends that reflect the evolving landscape of healthcare for patients suffering from this autoimmune disorder. A significant trend is the increasing awareness and diagnosis of celiac disease among the French population. This rise in recognition is driven by improved education on gluten-related disorders, supported by initiatives from health authorities. Consequently, more patients are seeking treatment options that not only manage their symptoms but also promote overall health, highlighting a shift towards holistic treatment approaches.  Another important aspect is the growing demand for gluten-free products, including those that cater specifically to the dietary needs of celiac patients.Due to customer demand for healthy options, the French food industry is responding positively by creating gluten-free alternatives. This shift is largely due to government efforts endorsing and subsidizing the promotion of gluten-free diets to enhance the quality of life for people with gluten sensitivity, as well as ensuring food safety measures for celiac patients.  There is an opportunity in the broadening of accessible intervention strategies as well as in the development of research aimed at developing specific treatments. France’s health system is concentrating on the celiac disease functional unit of personalized medicine, which may improve the treatment processes for patients suffering from celiac disease. There is also potential for growth in nutritional counseling and education services, which inform patients about dietary choices, benefiting from the supportive role of NGOs. Recent times have shown an uptick in collaboration between healthcare providers, food manufacturers, and patient advocacy groups. These partnerships aim to create a safer environment for those with celiac disease, particularly by emphasizing transparency in food labeling. This trend signifies a collective effort to improve the daily lives of those affected, ensuring they have access to relevant information and safe dietary options in the French market. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** **France Celiac Disease Treatment Market Drivers** **Increase in Celiac Disease Awareness** The growing awareness about Celiac Disease among both healthcare professionals and the general population is significantly driving the France Celiac Disease Treatment Market Industry. Campaigns initiated by organizations such as the French Association of People with Celiac Disease have contributed to increasing public knowledge about the condition, leading to better diagnosis and treatment avenues.  It's estimated that approximately 1 in 100 people globally are affected by Celiac Disease, yet many remain undiagnosed.In France, the estimated prevalence of diagnosed cases has increased by around 20% over the last decade, prompting a surge in demand for effective treatments. Furthermore, France's Ministry of Health has recognized the need for increased education and awareness programs, contributing to the growing market dynamics by facilitating healthcare access and improving patient outcomes. **Advancements in Medical Research and Treatment Options** The France Celiac Disease Treatment Market Industry is experiencing significant momentum due to ongoing advancements in medical research and the development of novel treatment options. Research initiatives, notably supported by public institutions such as Inserm (the French National Institute of Health and Medical Research), have led to innovative therapies beyond the gluten-free diet traditionally employed.  Reports indicate a 15% increase in funding earmarked for Celiac Disease research in the past three years, promoting trials and advancements in therapeutic areas like enzyme replacement and immunotherapy.As these innovative treatments enter trials and eventual markets, they are set to enhance patient quality of life, thereby stimulating market growth. **Government Support and Policy Reforms** Government initiatives and supportive policies are playing a pivotal role in shaping the France Celiac Disease Treatment Market. New legislation concerning food safety standards and the accessibility of gluten-free products has been introduced, reflecting a commitment to the health of individuals with Celiac Disease. The French government has reported a 30% increase in subsidization for gluten-free food products in the past five years, making them more accessible to patients.These policies are critical in reducing the financial burden on families and improving treatment adherence, which is vital for the overall effectiveness of Celiac Disease management, paving the way for further market growth. **Rising Prevalence of Autoimmune Diseases** The increasing prevalence of autoimmune diseases, with Celiac Disease being one of the prevalent disorders, is a significant driver for the France Celiac Disease Treatment Market Industry. Recent statistics from the French Health Ministry indicate that autoimmune diseases affect approximately 5% of the French population, with a notable rise in the diagnosis of Celiac Disease.  This correlates with broader trends in healthcare that emphasize the need for targeted treatment plans.Consequently, as the incidence of autoimmune disorders rises, so does the awareness and demand for specialized treatment solutions, enhancing the overall market dynamics. **France Celiac Disease Treatment Market Segment Insights** **Celiac Disease Treatment Market Treatment Type Insights** The France Celiac Disease Treatment Market is experiencing notable growth, primarily driven by the increasing prevalence of celiac disease among the population. This market can be segmented based on Treatment Type, which encompasses a variety of approaches to manage this autoimmune disorder. Key areas of focus within this segment include the Gluten Free Diet, Vitamin and Minerals Supplements, and Medical Therapies, each contributing uniquely to the overall treatment landscape. The Gluten Free Diet is often the cornerstone of managing celiac disease, as it directly addresses the root cause by eliminating gluten from the patient's diet, thus promoting healing of the intestinal lining.  In France, consumer awareness about gluten intolerance has surged, leading to a broader acceptance and availability of gluten-free products across supermarkets and restaurants, thereby significantly enhancing the adoption of this treatment method. Vitamin and Minerals Supplements hold substantial importance in the treatment of celiac disease, as individuals affected often suffer from nutritional deficiencies due to malabsorption. These supplements play a crucial role in replenishing essential nutrients, improving the quality of life for patients, and mitigating potential health complications. The demand for these supplements has grown as more patients recognize the need for a comprehensive management plan that includes adequate nutrition alongside dietary restrictions. Medical Therapies represent an evolving area within the France Celiac Disease Treatment Market, characterized by increasing Research and Development initiatives aimed at developing novel therapies to manage symptoms and enhance the patients' quality of life. While dietary management remains the gold standard, innovative treatments are being explored to provide alternatives for those who may struggle with adherence to a strict gluten-free diet. This segment reflects the industry's commitment to not only addressing the dietary needs of patients but also exploring avenues for additional support through pharmacological means. Overall, the Treatment Type segment of the France Celiac Disease Treatment Market showcases a multifaceted approach where each area contributes to a holistic management strategy for this chronic condition. As the market continues to evolve, patients and healthcare providers are likely to benefit from advancements in these segments, ensuring a more comprehensive understanding and approach to celiac disease management. The interplay among these treatment types highlights the importance of tailored patient care and the ongoing need for educational initiatives promoting awareness and understanding of celiac disease and its treatment options.  Notably, these trends align with the growing focus on public health initiatives in France, seen as the government actively encourages healthy dietary practices. Consequently, the France Celiac Disease Treatment Market remains dynamic, poised for continued growth and innovation in response to the evolving needs of patients and the healthcare system. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** **Celiac Disease Treatment Market End User Insights** The France Celiac Disease Treatment Market, centered around the End User segment, is characterized by diverse demand driven by various healthcare settings, notably Hospitals and Clinics, Research Centers, and others. Hospitals and Clinics play a pivotal role in diagnosis and management, providing essential care and treatment to patients suffering from celiac disease, which is increasingly recognized in France. Research Centers are crucial for advancing knowledge and treatment options in this domain, often pioneering studies on gluten intolerance and innovative therapies to manage the disease. The Others category includes outpatient care facilities and home healthcare services, which are gaining traction, particularly as patient preferences shift towards more personalized care. This segmentation illustrates the multifaceted nature of service delivery in managing celiac disease and highlights the importance of integrated care models that ensure comprehensive treatment. Growing awareness of celiac disease among the population, alongside ongoing research efforts, supports market growth and reflects a trend toward increased accessibility and improved health outcomes for affected patients in France.With a significant rise in diagnosed cases contributing to demand, each segment plays a vital role in the overall France Celiac Disease Treatment Market landscape. **France Celiac Disease Treatment Market Key Players and Competitive Insights** The competitive landscape of the France Celiac Disease Treatment Market is characterized by a myriad of companies dedicated to addressing the unique healthcare needs of those affected by celiac disease. This market is increasingly driven by the rising awareness of celiac disease and its impact on health, leading to an expansion of treatment options, ranging from gluten-free food products to medication aimed at alleviating symptoms. The focus on improving patient outcomes and quality of life has prompted companies to innovate and adapt their offerings to meet the changing demands of consumers and healthcare providers.  The competitive insights reveal a dynamic environment where collaboration, research, and an understanding of patient needs play a crucial role in shaping market strategies.Carondelet has successfully established a strong presence within the France Celiac Disease Treatment Market through its comprehensive approach to healthcare solutions. The company leverages its strengths in specialized products tailored for individuals with celiac disease, ensuring that the offerings are not only effective but also adhere to strict dietary requirements. Carondelet's reputation for quality and effectiveness in treatment options positions it favorably among consumers and healthcare practitioners alike.  The company also emphasizes ongoing research and development to enhance its product portfolio, which has fostered trust and loyalty among patients. The commitment to understanding the specific challenges faced by individuals with celiac disease has allowed Carondelet to maintain a competitive edge in this niche market.Pharmavite plays a significant role in the France Celiac Disease Treatment Market by providing a range of specialized products designed to support the dietary needs of individuals with celiac disease. The company's key offerings include gluten-free supplements that enhance nutrition while being compliant with dietary restrictions.  Pharmavite's strength lies in its focus on high-quality ingredients and formulations backed by scientific research, which resonates well with health-conscious consumers. The company has made strategic partnerships and investments aimed at expanding its market footprint in France, thus increasing accessibility to its products. Further, Pharmavite continues to explore potential mergers and acquisitions to bolster its presence and enhance its product offerings within the French market, thereby catering to the growing demand for effective celiac disease treatments. **Key Companies in the France Celiac Disease Treatment Market Include** **France Celiac Disease Treatment Market Industry Developments** The France Celiac Disease Treatment Market has witnessed significant developments in recent months, particularly with the growing awareness and diagnosis rates of celiac disease within the country. Innovative solutions and treatments are increasingly being researched and introduced by key players such as Merck, GlaxoSmithKline, and Sanofi. In February 2023, Merck announced advancements in biopharmaceuticals that could enhance treatment efficacy. Notably, in April 2023, AbbVie secured regulatory approval for its new celiac treatment, signaling growth potential in the market, backed by robust research initiatives.  The increasing collaboration among these companies has led to expanded treatment options, driven by demand for gluten-free products and therapies. Additionally, a surge in consumer interest in nutritional supplements has benefited Pharmavite and Nestle, contributing to the growth of the market. The overall market valuation continues to rise as the French government promotes health initiatives for celiac disease, emphasizing public health education on gluten intolerance and its associated health implications. The trend of mergers and acquisitions remains prevalent; however, no recent significant mergers involving the focused companies have been documented within this framework. **France Celiac Disease Treatment Market Segmentation Insights** ## Market Drivers ### Supportive Government Policies Supportive government policies in France are playing a pivotal role in shaping the celiac disease-treatment market. The French government has implemented various initiatives aimed at improving the quality of life for individuals with celiac disease, including subsidies for gluten-free products and funding for research into the condition. These policies are designed to alleviate the financial burden on patients and encourage adherence to gluten-free diets. As a result, the celiac disease-treatment market is likely to experience growth, as more individuals are empowered to seek appropriate treatments and dietary options. Furthermore, government support for awareness campaigns may enhance public understanding of celiac disease, further driving market demand. ### Growing Awareness of Celiac Disease The increasing awareness of celiac disease among the French population is a crucial driver for the celiac disease-treatment market. Educational campaigns and initiatives by health organizations have led to a better understanding of the disease, its symptoms, and the importance of adhering to a strict gluten-free diet. This heightened awareness is reflected in the rising number of diagnoses, with estimates suggesting that approximately 1 in 100 individuals in France may be affected. Consequently, the demand for gluten-free products and treatments is expected to grow, propelling the celiac disease-treatment market forward. As more individuals seek medical advice and dietary guidance, healthcare providers are likely to expand their offerings, further stimulating market growth. ### Advancements in Diagnostic Technologies Recent advancements in diagnostic technologies are significantly impacting the celiac disease-treatment market. Improved testing methods, such as serological tests and genetic testing, have enhanced the accuracy and speed of celiac disease diagnoses. In France, the introduction of these innovative diagnostic tools has led to an increase in the identification of previously undiagnosed cases. This surge in diagnoses is likely to drive demand for treatment options, including specialized dietary plans and gluten-free products. As healthcare providers adopt these advanced technologies, the celiac disease-treatment market is expected to expand, catering to a growing population of diagnosed individuals seeking effective management solutions. ### Rising Incidence of Autoimmune Disorders The rising incidence of autoimmune disorders in France is a notable driver for the celiac disease-treatment market. Celiac disease, classified as an autoimmune condition, is increasingly recognized as part of a broader trend of autoimmune diseases affecting the population. Studies indicate that the prevalence of autoimmune disorders has been on the rise, which may correlate with environmental factors and lifestyle changes. This trend is likely to lead to a greater focus on celiac disease, prompting healthcare professionals to prioritize screening and treatment options. As awareness of the link between autoimmune disorders and celiac disease grows, the market for effective treatment solutions is expected to expand, catering to a larger patient base. ### Increased Availability of Gluten-Free Products The increased availability of gluten-free products in France is a significant driver for the celiac disease-treatment market. Retailers and manufacturers are responding to the growing demand for gluten-free options, resulting in a wider range of products being offered in supermarkets and specialty stores. This trend is supported by market data indicating that the gluten-free food market in France is projected to reach approximately €1 billion by 2026. As consumers become more health-conscious and seek gluten-free alternatives, the celiac disease-treatment market is likely to benefit from this expansion. The availability of diverse gluten-free products not only supports those diagnosed with celiac disease but also attracts a broader audience interested in gluten-free diets. ## Future Outlook The [Celiac Disease Treatment Market](https://www.marketresearchfuture.com/reports/celiac-disease-treatment-market-8474) in France is projected to grow at a 10.78% CAGR from 2025 to 2035, driven by increasing awareness and innovative treatment options. **New opportunities:** - Development of personalized gluten-free meal plans for patients - Expansion of telehealth services for remote patient monitoring - Investment in research for novel therapeutic agents targeting celiac disease By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Treatment Type: Gluten Free Diet (Largest) vs. Vitamin and Minerals Supplements (Fastest-Growing) In the France celiac disease-treatment market, the segment distribution reveals that the Gluten Free Diet holds the largest share, catering to the primary needs of patients. This dietary approach remains the cornerstone of treatment, fundamentally defining dietary habits for those with celiac disease. Vitamin and Minerals Supplements, while still a crucial support component, capture an increasing share as these products rise in prominence among celiac patients seeking additional health benefits. Growth trends indicate a steady increase in acceptance of Vitamin and Minerals Supplements as understanding of celiac disease expands. This segment is driven by heightened awareness of nutritional deficiencies stemming from gluten avoidance. The demand for robust and tailored supplementation is expected to surge, alongside a growing trend towards integrated health solutions that personalize patient care in the France celiac disease-treatment market. Gluten Free Diet: Dominant vs. Vitamin and Minerals Supplements: Emerging The Gluten Free Diet stands out as the dominant treatment type within the France celiac disease-treatment market, providing essential dietary restrictions necessary for managing celiac disease effectively. It emphasizes the complete avoidance of gluten, enabling individuals to alleviate symptoms significantly and maintain overall health. On the other hand, Vitamin and Minerals Supplements emerge as an increasingly important segment, catering to the growing recognition of nutritional deficiencies that may arise due to strict gluten-free diets. These supplements are tailored to support holistic health and address specific dietary gaps, appealing to health-conscious consumers seeking to enhance their overall wellness while managing their celiac condition. ### By End User: Hospitals and Clinics (Largest) vs. Research Centers (Fastest-Growing) The France celiac disease-treatment market shows a significant distribution among its end user segments, with hospitals and clinics leading the market due to their established healthcare infrastructure and patient accessibility. This segment accounts for the majority share, driven by the high volume of patients seeking treatment and ongoing management of celiac disease. In contrast, research centers are emerging as a fast-growing segment, fueled by increased investment in celiac disease research and innovations in treatment options. Growth trends in the end user segment are largely influenced by the rising awareness of celiac disease and the demand for specialized treatments. Hospitals and clinics benefit from longstanding healthcare networks and patient trust, while research centers are gaining traction through collaborations with pharmaceutical companies and academic institutions. This dual growth reflects a dynamic market landscape, catering to both immediate healthcare needs and long-term research advancements. Hospitals and Clinics (Dominant) vs. Research Centers (Emerging) Hospitals and clinics remain dominant in the France celiac disease-treatment market, providing comprehensive care and a variety of treatment options for patients. Their established protocols and multi-disciplinary teams ensure effective management of the disease, making them the preferred choice for patients. On the other hand, research centers are positioning themselves as an emerging force, focusing on innovative research and clinical trials. These centers are crucial for advancing treatment methodologies and improving patient outcomes. They attract funding for studies that explore new therapies, contributing to the overall growth of the treatment landscape. The synergy between these two segments fosters a robust ecosystem, balancing immediate patient care with the pursuit of future solutions. ## Competitive Benchmarking The celiac disease-treatment market in France is characterized by a dynamic competitive landscape, driven by increasing awareness of gluten intolerance and a growing demand for gluten-free products. Key players such as General Mills (US), Nestle (CH), and Dr. Schar (IT) are actively shaping the market through innovative product offerings and strategic partnerships. General Mills (US) has positioned itself as a leader in the gluten-free segment by focusing on product diversification and enhancing its supply chain capabilities. Meanwhile, Nestle (CH) emphasizes sustainability in its operations, aligning its product development with consumer preferences for healthier and environmentally friendly options. Dr. Schar (IT) continues to leverage its expertise in gluten-free products, enhancing its market presence through targeted marketing strategies and collaborations with health professionals.The business tactics employed by these companies include localizing manufacturing to reduce costs and optimize supply chains, which is particularly crucial in a moderately fragmented market. The collective influence of these key players fosters a competitive environment where innovation and responsiveness to consumer needs are paramount. This structure allows for a variety of product offerings, catering to diverse consumer preferences while maintaining competitive pricing. In August General Mills (US) announced the launch of a new line of gluten-free snacks aimed at children, which reflects a strategic move to capture a younger demographic. This initiative not only broadens their product portfolio but also positions the company to tap into the growing trend of health-conscious parents seeking gluten-free options for their children. The introduction of these snacks is expected to enhance brand loyalty and increase market share in the gluten-free segment. In September Nestle (CH) unveiled a partnership with a leading health technology firm to develop a digital platform that provides personalized dietary recommendations for individuals with celiac disease. This strategic action underscores Nestle's commitment to integrating technology into its product offerings, potentially revolutionizing how consumers interact with gluten-free diets. By leveraging data analytics, the company aims to enhance customer engagement and drive sales through tailored solutions. In October Dr. Schar (IT) expanded its distribution network by entering into a collaboration with major retail chains across France, significantly increasing its market reach. This strategic move is likely to enhance product availability and visibility, catering to the rising demand for gluten-free products. By strengthening its distribution channels, Dr. Schar aims to solidify its position as a market leader in the gluten-free sector. As of November current competitive trends indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in product development and marketing strategies. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise to innovate more effectively. Looking ahead, competitive differentiation is expected to evolve from traditional price-based competition to a focus on innovation, technology, and supply chain reliability, as companies strive to meet the sophisticated demands of health-conscious consumers. ## Recent News & Developments The France Celiac Disease Treatment Market has witnessed significant developments in recent months, particularly with the growing awareness and diagnosis rates of celiac disease within the country. Innovative solutions and treatments are increasingly being researched and introduced by key players such as Merck, GlaxoSmithKline, and Sanofi. In February 2023, Merck announced advancements in biopharmaceuticals that could enhance treatment efficacy. Notably, in April 2023, AbbVie secured regulatory approval for its new celiac treatment, signaling growth potential in the market, backed by robust research initiatives.  The increasing collaboration among these companies has led to expanded treatment options, driven by demand for gluten-free products and therapies. Additionally, a surge in consumer interest in nutritional supplements has benefited Pharmavite and Nestle, contributing to the growth of the market. The overall market valuation continues to rise as the French government promotes health initiatives for celiac disease, emphasizing public health education on gluten intolerance and its associated health implications. The trend of mergers and acquisitions remains prevalent; however, no recent significant mergers involving the focused companies have been documented within this framework. ## Report Scope | MARKET SIZE 2024 | 27.48(USD Million) | | --- | --- | | MARKET SIZE 2025 | 30.44(USD Million) | | MARKET SIZE 2035 | 84.77(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.78% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Gluten Free Holdings (US), General Mills (US), Kraft Heinz (US), Nestle (CH), Dr. Schar (IT), Boulder Brands (US), Canyon Bakehouse (US), Udi's Gluten Free (US) | | Segments Covered | Treatment Type, End User | | Key Market Opportunities | Emerging gluten-free product innovations cater to increasing consumer demand in the celiac disease-treatment market. | | Key Market Dynamics | Rising demand for gluten-free products drives innovation in celiac disease treatment options and regulatory adaptations. | | Countries Covered | France | ## Frequently Asked Questions **Q: What was the market valuation for the France celiac disease-treatment market in 2024?** A: The market valuation for the France celiac disease-treatment market was $27.48 Million in 2024. **Q: What is the projected market valuation for the France celiac disease-treatment market by 2035?** A: The projected market valuation for the France celiac disease-treatment market is $84.77 Million by 2035. **Q: What is the expected CAGR for the France celiac disease-treatment market during the forecast period 2025 - 2035?** A: The expected CAGR for the France celiac disease-treatment market during the forecast period 2025 - 2035 is 10.78%. **Q: Which treatment type segment had the highest valuation in 2024?** A: In 2024, the Gluten Free Diet segment had the highest valuation at $32.67 Million. **Q: What are the key players in the France celiac disease-treatment market?** A: Key players in the France celiac disease-treatment market include Gluten Free Holdings, General Mills, Kraft Heinz, Nestle, Dr. Schar, Boulder Brands, Canyon Bakehouse, and Udi's Gluten Free. **Q: What was the valuation of the Vitamin and Minerals Supplements segment in 2024?** A: The valuation of the Vitamin and Minerals Supplements segment was $8.24 Million in 2024. **Q: Which end user segment is projected to grow the most by 2035?** A: The Hospitals and Clinics end user segment is projected to grow the most, reaching $32.77 Million by 2035. **Q: What was the valuation of Medical Therapies in 2024?** A: The valuation of Medical Therapies in 2024 was $8.25 Million. **Q: How does the valuation of Research Centers compare to other end user segments in 2024?** A: In 2024, the valuation of Research Centers was $8.24 Million, indicating a competitive position among other end user segments. **Q: What is the projected growth trend for the Gluten Free Diet segment from 2024 to 2035?** A: The Gluten Free Diet segment is expected to show substantial growth, with projections indicating a rise to $32.67 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/france-celiac-disease-treatment-market-51358*